The CRO has opened a new clinic in response to demand for early-stage research, specifically for Alzheimer’s Disease, and expanded its footprint in India to conduct studies ‘at favorable pricing with faster timelines,’ say company executives.
Clinical trials in the UK are reportedly declining as the country grapples with Brexit – a change which could make access to preclinical and bioanalytical research materials, including NHPs, problematic, says QPS.
QPS is expanding ‘aggressively’ at its US-based headquarters, rebuilding on a rolling basis to support a growing demand for gene therapy treatments, says VP.
QPS has expanded its Phase I clinical trial capabilities by more than 20% and doubled its lab space, which will allow the CRO to accommodate ‘exponentially more sponsors’ as demand continues to increase.
